Goldman Sachs
AMED

Goldman Sachs’s Amedisys AMED Stock Holding History

Goldman Sachs’s Portfolio AMED Stock Details AMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-242,944
Closed -$23.9M – 6314
2025
Q2 		$23.9M Buy
242,944
+140,094
+136% +$13.3M ﹤0.01% 1975
2025
Q1 		$9.53M Sell
102,850
-54,865
-35% -$5.06M ﹤0.01% 2745
2024
Q4 		$14.3M Buy
157,715
+59,368
+60% +$5.45M ﹤0.01% 2444
2024
Q3 		$9.49M Sell
98,347
-1,009,492
-91% -$98.5M ﹤0.01% 2784
2024
Q2 		$102M Buy
1,107,839
+1,043,958
+1,634% +$96.9M 0.02% 786
2024
Q1 		$5.89M Sell
63,881
-70,629
-53% -$6.62M ﹤0.01% 2943
2023
Q4 		$12.8M Buy
134,510
+31,831
+31% +$2.97M ﹤0.01% 2301
2023
Q3 		$9.59M Buy
102,679
+8,368
+9% +$773K ﹤0.01% 2422
2023
Q2 		$8.62M Buy
94,311
+42,550
+82% +$3.49M ﹤0.01% 2594
2023
Q1 		$3.81M Sell
51,761
-56,049
-52% -$4.85M ﹤0.01% 3307
2022
Q4 		$9.01M Buy
107,810
+17,074
+19% +$1.54M ﹤0.01% 2678
2022
Q3 		$8.78M Buy
90,736
+17,030
+23% +$2.03M ﹤0.01% 2633
2022
Q2 		$7.75M Buy
73,706
+11,982
+19% +$1.53M ﹤0.01% 2747
2022
Q1 		$10.6M Sell
61,724
-3,640
-6% -$544K ﹤0.01% 2626
2021
Q4 		$10.6M Sell
65,364
-7,695
-11% -$1.24M ﹤0.01% 2706
2021
Q3 		$10.9M Buy
73,059
+4,787
+7% +$995K ﹤0.01% 2640
2021
Q2 		$16.7M Sell
68,272
-4,690
-6% -$1.23M ﹤0.01% 2220
2021
Q1 		$19.3M Sell
72,962
-15,722
-18% -$4.43M ﹤0.01% 1959
2020
Q4 		$26M Buy
88,684
+26,358
+42% +$6.76M 0.01% 1633
2020
Q3 		$14.7M Sell
62,326
-84,934
-58% -$19.3M ﹤0.01% 1986
2020
Q2 		$29.2M Buy
147,260
+59,095
+67% +$11M 0.01% 1378
2020
Q1 		$16.2M Sell
88,165
-40,239
-31% -$7.16M 0.01% 1678
2019
Q4 		$21.4M Buy
128,404
+26,771
+26% +$3.98M 0.01% 1792
2019
Q3 		$13.3M Buy
101,633
+15,468
+18% +$2.01M ﹤0.01% 2129
2019
Q2 		$10.5M Sell
86,165
-99,760
-54% -$11.8M ﹤0.01% 2329
2019
Q1 		$22.9M Sell
185,925
-113,091
-38% -$14.2M 0.01% 1759
2018
Q4 		$35M Sell
299,016
-35,511
-11% -$4.19M 0.01% 1365
2018
Q3 		$41.8M Buy
334,527
+55,169
+20% +$6.09M 0.01% 1358
2018
Q2 		$23.9M Sell
279,358
-77,115
-22% -$5.66M 0.01% 1746
2018
Q1 		$21.5M Buy
356,473
+206,779
+138% +$11.8M 0.01% 1803
2017
Q4 		$7.89M Buy
149,694
+59,609
+66% +$3.14M ﹤0.01% 2646
2017
Q3 		$5.04M Buy
90,085
+36,896
+69% +$1.95M ﹤0.01% 3130
2017
Q2 		$3.34M Sell
53,189
-115,898
-69% -$6.75M ﹤0.01% 3391
2017
Q1 		$8.64M Buy
169,087
+22,883
+16% +$1.09M ﹤0.01% 2514
2016
Q4 		$6.23M Buy
146,204
+24,835
+20% +$1.06M ﹤0.01% 2861
2016
Q3 		$5.76M Buy
121,369
+11,543
+11% +$576K ﹤0.01% 2918
2016
Q2 		$5.54M Buy
109,826
+48,242
+78% +$2.44M ﹤0.01% 2775
2016
Q1 		$2.98M Buy
61,584
+21,535
+54% +$831K ﹤0.01% 3144
2015
Q4 		$1.57M Sell
40,049
-29,036
-42% -$1.16M ﹤0.01% 3843
2015
Q3 		$2.62M Buy
69,085
+37,267
+117% +$1.57M ﹤0.01% 3511
2015
Q2 		$1.26M Buy
+31,818
New +$991K ﹤0.01% 4310
2014
Q4 		– Sell
-13,546
Closed -$273K – 7097
2014
Q3 		$273K Sell
13,546
-32,580
-71% -$629K ﹤0.01% 5849
2014
Q2 		$772K Buy
46,126
+9,825
+27% +$139K ﹤0.01% 4939
2014
Q1 		$541K Sell
36,301
-60,470
-62% -$931K ﹤0.01% 5213
2013
Q4 		$1.42M Buy
96,771
+46,411
+92% +$747K ﹤0.01% 4424
2013
Q3 		$867K Sell
50,360
-29,523
-37% -$438K ﹤0.01% 4712
2013
Q2 		$927K Buy
+79,883
New +$915K ﹤0.01% 4455

Other funds holding AMED

Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
MCI
MRP Capital Investments Alpharetta, Georgia $115M AUM 48.08% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Goldman Sachs's AMED Position: Q3 2025 in Review

Goldman Sachs sold out of Amedisys (AMED) in Q3 2025, closing a stake of 242,944 shares — an estimated $23.9M sold.

Goldman Sachs first reported a position in AMED in Q2 2013 and held it in 47 quarters. The position peaked at $102M in Q2 2024. 4 funds tracked by Wall St. Rank hold AMED as of Q3 2025.

  • Goldman Sachs reported no remaining Amedisys position as of Q3 2025 after selling out during the quarter.
  • Goldman Sachs sold 242,944 Amedisys shares in Q3 2025, an estimated $23.9M.
  • Goldman Sachs first reported a position in Amedisys in Q2 2013 and held it in 47 quarters.
  • Goldman Sachs's Amedisys position peaked at $102M in Q2 2024.
  • 4 funds tracked by Wall St. Rank held Amedisys as of Q3 2025.

Based on Goldman Sachs's 13F filing for Q3 2025, filed 14 Nov 2025.